About Us

As part of the Konica Minolta family, we uniquely unite genetics, imaging and pathology to help pharmaceutical developers and clinicians realize more precise, individualized applications that enable more prescriptive, proactive and preventive care. We bring together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise.

Leadership Team

Dr. Ken Bloom

CMO, Advanced Pathology & Genomic Services

Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.

Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.

Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.

Dr. Jack Hoppin

Co-founder and CEO, Invicro

Jack Hoppin, Ph.D., is chief executive officer and co-founder of Invicro, a global leading provider of imaging services, software solutions, and advanced data analysis in research and drug development. Dr. Hoppin oversees the overall corporate strategy and direction to ensure sponsors receive the highest standard of service through collaborative R&D, business development, operational excellence and valuable partnerships.

Dr. Hoppin co-founded Invicro with co-founder Dr. Christian Lackas, and founding partners Janna Murgia and Dr. Jacob Hesterman in late 2008. Today, Invicro has grown its team of professionals to 340+ strong, including over 200 research scientists- consisting of more than 60 MDs or Ph.Ds. Currently, Invicro has over 350 pre-clinical and clinical research trials open, and has realized about a 90% CAGR since it first full year of business in 2009. In 2017, Invicro was sold to Konica Minolta to integrate synergistic capabilities under the precision medicine offering, specifically the novel quantitative pathology technology invented by Konica Minolta. The company operates out of four core office and laboratory locations including its headquarters in Boston, as well as New Haven- CT, Doylestown-PA, and London-U.K. Invicro was honored for two consecutive years by Inc. Magazine as one of the fastest growing privately held companies in the U.S. in 2013 and 2014.

Prior to Invicro, from 2006 to 2009, Dr. Hoppin served as vice president of Imaging Systems at Bioscan Inc. in New York, NY. As vice president, Dr. Hoppin oversaw Bioscan’s lion share of the business – bringing the imaging product line to market through product development, research collaborations, and ensuring the technical sales and application support were fully aligned and succinctly executed. From 2005 to 2006, Dr. Hoppin was a project manager for Bioscan based out of Aachen, Germany and Budapest, Hungary, where he managed the development, and launch of the NanoSPET/CT system that went on to win multiple innovation awards and generated over 100 million dollars of revenue.

Prior to his industry experience, Dr. Hoppin was the Alexander von Humboldt post-doctoral fellow at the Research Center Jülich, Center for Electronics in Jülich, Germany from 2003 to 2005.

Dr. Hoppin holds four patents and over 30 peer-reviewed articles. Dr. Hoppin received his Ph.D. in applied mathematics from the University of Arizona, and is active in multiple academic societies serving on the Board of Trustees for the World Molecular Imaging Society, the Industry Board for the Society of Nuclear Medicine and a member of the Harvard Catalyst Biomarker Faculty.

Scientific Advisory Board Members

David Rimm, MD, PhD

Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine

Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is boarded in Anatomic and Cytopatholgy. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs. His lab is involved in testing new high-plex methods including imaging mass cytometry (Fluidigm) and digital spatial profiling (NanoString) He also has supported projects related to rapid, low cost diagnostic tests and direct tissue imaging. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 350 peer-reviewed papers and 8 patents.

Howard I. Scher

Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative

Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors. Most recently Dr. Scher was elected to the Association of American Physicians and named a Fellow of the American Society of Clinical Oncology (ASCO).